ARTICLE | Company News
Inflazyme autoimmune, inflammation news
August 2, 2004 7:00 AM UTC
IZP restructured its R&D efforts to focus on its Complement Inhibition and Prodaptin technologies. The company will reduce its headcount by 42, or about half, to 40. Positions will be cut across the c...